About Codiak BioSciences
Codiak BioSciences is a company based in Cambridge (United States) founded in 2015. Codiak BioSciences has raised $168.5 million across 3 funding rounds from investors including Fidelity Investments, ARE and Flagship Pioneering. The company has 48 employees as of December 31, 2022. Codiak BioSciences operates in a competitive market with competitors including Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
- Headquarter Cambridge, United States
- Employees 48 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Codiak Biosciences, Inc.
-
Annual Revenue
$22.94 M (USD)687as on Dec 31, 2021
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$168.5 M (USD)
in 3 rounds
-
Latest Funding Round
$76.5 M (USD), Series C
Nov 29, 2017
-
Investors
Fidelity Investments
& 10 more
-
Employee Count
48
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Codiak BioSciences
Codiak BioSciences has successfully raised a total of $168.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $76.5 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Codiak BioSciences
Codiak BioSciences has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, ARE and Flagship Pioneering.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked |
Investor details for Codiak BioSciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Codiak BioSciences
Investment portfolio details for Codiak BioSciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Codiak BioSciences
Detailed financials for Codiak BioSciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Codiak Biosciences Comparisons
Peer comparison for Codiak BioSciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Codiak BioSciences
Codiak BioSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| Locked | Locked | Locked |
MicroRNA profiling platform is developed to detect genes in samples.
|
Detailed competitors of Codiak BioSciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Codiak Biosciences
Complete news archive for Codiak BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Codiak BioSciences
Codiak BioSciences was founded in 2015.
Codiak BioSciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Codiak BioSciences is a funded company, having raised a total of $168.5M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Codiak BioSciences is 48.
Annual revenue of Codiak BioSciences is $22.94M as on Dec 31, 2021.
Founded in 2015 in Cambridge, United States, exosome-based therapeutics and diagnostics for cancer are developed by Codiak BioSciences in the biotechnology sector. Natural vesicles mediating intercellular communication are employed for treatment and diagnostic applications. Key products include exoSTING for solid tumors, exoIL-12 for melanoma, and exoASO-STAT3 for hematologic and hepatic cancers, with operations centered on advancing these solutions.
Codiak BioSciences's top competitors include Guardant Health, GRAIL and BillionToOne.
Codiak BioSciences has 11 investors. Key investors include Fidelity Investments, ARE, Flagship Pioneering, Arch Venture Partners, and Alaska Permanent Fund.